Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 40188, held by Oxford Pharms. Carisoprodol.
As of Nov 16, 2026, ANDA 40188 (Carisoprodol), held by Oxford Pharms, was first approved by FDA on Mar 7, 1997, with 1 approved supplement and 0 published complete response letters.
Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration..
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Oct 29, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Mar 7, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters